By Marla Sommer 29 September 2022 Dr Thomas Tapmeier has been awarded a combined $100K to develop new antagonists against the Neuropeptide S Receptor 1Congratulations to Dr Thomas Tapmeier of the Uterine Biology and Gynaecological Diseases group at the Department of Obstetrics and Gynaecology, who has been awarded a combined $100K from Therapeutic Innovation Australia (TIA) and the Monash Research Impact Fund (MRIF) to develop new antagonists against the Neuropeptide S Receptor 1 (NPSR1).'I am delighted! This is a wonderful opportunity to drive the search for new and better treatments for endometriosis — and other indications — forward.

https://www.monash.edu/medicine/news/latest/2022-articles/combating-endometriosis-related-pain-with-$100k

#monash